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Abstract Gerhard Levy started his investigations on the
‘‘Kinetics of Drug Action in Disease States’’ in the fall of
1980. The objective of his research was to study inter-
individual variation in pharmacodynamics. To this end,
theoretical concepts and experimental approaches were
introduced, which enabled assessment of the changes in
pharmacodynamics per se, while excluding or accounting
for the cofounding effects of concomitant changes in
pharmacokinetics. These concepts were applied in several
studies. The results, which were published in 45 papers in
the years 1984–1994, showed considerable variation in
pharmacodynamics. These initial studies on kinetics of
drug action in disease states triggered further experimental
research on the relations between pharmacokinetics and
pharmacodynamics. Together with the concepts in Levy’s
earlier publications ‘‘Kinetics of Pharmacologic Effects’’
(Clin Pharmacol Ther 7(3): 362–372, 1966) and ‘‘Kinetics
of pharmacologic effects in man: the anticoagulant action
of warfarin’’ (Clin Pharmacol Ther 10(1): 22–35, 1969),
they form a significant impulse to the development of
physiology-based pharmacodynamic (PBPD) modeling as
novel discipline in the pharmaceutical sciences. This paper
reviews Levy’s research on the ‘‘Kinetics of Drug Action
in Disease States’’. Next it addresses the significance of his
research for the evolution of PBPD modeling as a scientific
discipline. PBPD models contain specific expressions to
characterize in a strictly quantitative manner processes on
the causal path between exposure (in terms of
concentration at the target site) and the drug effect (in
terms of the change in biological function). Pertinent pro-
cesses on the causal path are: (1) target site distribution, (2)
target binding and activation and (3) transduction and
homeostatic feedback.
Keywords Biophase distribution  Receptor theory 
Dynamical systems analysis  Disease systems analysis
Introduction
Gerhard Levy started his investigations in the series ‘‘Ki-
netics of Drug Action in Disease States’’, in the fall of 1980.
At that time it was well-established that multiple factors
including certain diseases, changes in physiology, con-
comitant use of other drugs and environmental factors can
have profound effects on the pharmacokinetics of drugs [1].
Also, the awareness of large inter-individual variation in
pharmacokinetics had led to the introduction of therapeutic
drug concentration monitoring in clinical practice as the
basis for individualized optimization of drug dosage, yield-
ing plasma concentrations in a pre-defined therapeutic range
[2–4]. In this practice it was implicitly assumed that inter-
individual variation in pharmacodynamics is small. How-
ever, limited information was available on variation in
pharmacodynamics (i.e. drug concentration–effect rela-
tions). A review of the literature revealed that there are many
examples of altered drug response as result of disease, but
that in general it was not possible to determine the mecha-
nism of this altered response in terms of changes in phar-
macokinetics, pharmacodynamics or a combination of both.
In other words, the magnitude and the underlying mecha-
nisms of inter-individual variation in pharmacodynamics
were largely unknown. It were these observations that that
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made Levy decide to start systematic investigations on the
variation in pharmacodynamics in animal models of disease
[5]. It was the starting point of experimental research in
pharmacodynamics. Initially, in this research the emphasis
was on designing novel concepts and approaches by which,
in pharmacodynamic studies, the effects of potentially con-
founding changes in pharmacokinetics (e.g. changes in dis-
tribution, accumulation of metabolites) can be either
excluded or accounted for. Application of these approaches
in conjunction with the concepts from Levy’s earlier papers
on the kinetics of pharmacological effects [6] and the mod-
eling of the anticoagulant actions of warfarin [7] led to
fundamental insights in the relations between pharmacoki-
netics and pharmacodynamics. For example the concepts
from Levy’s key publication ‘‘Kinetics of pharmacologic
effects’’ [6] constituted the basis for the modeling of target
site distribution as a determinant of the time course of drug
effect. And the publication ‘‘Kinetics of pharmacologic
effects in man: the anticoagulant action of warfarin’’ [7]
constitutes the scientific basis for not only the modeling of
time dependencies in drug action resulting from an indirect
mechanism of action, but also the modeling of transduction
mechanisms, of homeostatic feedback and even the model-
ing of drug effects on disease progression. Rigorous animal
experiments, in which drugs were administered at widely
different rates and routes of administration, in which drug
and metabolite concentrations were measured in different
tissues, and where quantitative information on relevant
system properties such as the receptor density was obtained,
constituted the basis for development of mechanism-based
PKPD models with improved properties for extrapolation
and prediction. These contributions represent a significant
impulse to the development of physiology-based pharma-
codynamic (PBPD) modeling as a novel discipline in the
pharmaceutical sciences.
This paper reviews Levy’s research on the ‘‘Kinetics of
Drug Action in Disease States’’. Next it addresses the
significance of his research for the evolution of PBPD
modeling as a scientific discipline, focusing on models to
characterize: (1) the kinetics of target site distribution, (2)
the molecular mechanisms of variation in concentration–
effect relations, (3) the kinetics of transduction and
homeostatic feedback, and (4) the mechanism-based anal-
ysis of drug effects on disease progression.
Separating pharmacokinetic
and pharmacodynamic variability
Apparent changes in drug concentration–effect relation-
ships in disease states can be the result of changes in
pharmacokinetics, changes in pharmacodynamics, or both.
Therefore, to investigate the pharmacodynamic variability
in vivo, and to reveal the true magnitude of this variability,
it is important to apply experimental approaches by which
the effects of potentially confounding changes in pharma-
cokinetics are either excluded or accounted for. Potentially
confounding pharmacokinetic factors include: (1) changes
in distribution between the site where the drug concentra-
tions are measured and the site of action (the ‘‘biophase’’),
(2) changes in the disposition of enantiomers, (3) the for-
mation of active and/or interactive metabolites, and (4)
functional adaptation or tolerance development resulting
from variation in the duration of drug action. In this section
these approaches and their applications are discussed and
illustrated based on examples from the series on ‘‘Kinetics
of Drug Action in Disease States’’.
Target site distribution kinetics
Understanding variation in pharmacodynamics requires
information on the (free) drug concentration at the target
site. For drugs acting at extracellular targets this informa-
tion might be derived from the free drug concentrations in
plasma by postulating a ‘‘effect compartment’’ to account
for hysteresis as was elegantly demonstrated for
d-tubocurarine by Sheiner et al. [8]. To what extent this
also applied to other drugs which differ in target binding
kinetics or for drugs acting in different tissues, was largely
unknown. Moreover, for drugs acting in tissues that are
protected by specific barriers (i.e. the central nervous sys-
tem) or for drugs acting at intracellular targets (i.e. anti-
cancer drugs), the biophase distribution kinetics are likely
to be much more complex. Here changes in the perme-
ability of the barriers and/or the expression and function of
transporters may lead to apparently different plasma drug
concentration–effect relationships, while the underlying
target concentration–effect relation is unaltered. Or con-
versely, the free steady-state plasma concentration–effect
relationship may seem unaffected despite a change in the
underlying pharmacology. It was therefore deemed essen-
tial to develop approaches to approximate free drug con-
centration–effect relations to account for eventual disease
related variation in target distribution kinetics. This started
the research on identifying a compartment where drug and
metabolite concentrations could be measured and which
was, as we called it, ‘‘pharmacokinetically indistinguish-
able from the site of action’’ [5]. Here is a direct connection
to Levy’s 1966 paper on the kinetics of pharmacological
effects [6], where it is described how he had applied this
principle to demonstrate that the effect of d-tubocurarine
was related to concentrations in a peripheral compartment
of a multi-compartment pharmacokinetic model rather than
the concentrations in blood [9].
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In the first paper in the series on the kinetics of drug
action in disease states, we introduced the concept of
infusion of sedative drugs to a predefined degree of seda-
tion (loss of righting reflex, LRR) to identify a site where
drug concentrations were in direct equilibrium with the
target site, to ultimately be able to study changes in the
brain sensitivity to sedative and anesthetic drugs [5]. For
this first study, phenobarbital was chosen as a model drug,
because of its favorable pharmacokinetic properties, in that
unlike many other barbiturates, phenobarbital is not an
enantiomeric drug. Moreover, the drug is slowly metabo-
lized and p-hydroxy-phenobarbital had been identified as
its major metabolite, which was commercially available,
and of which the effects could be studied. A specific fea-
ture of using drug concentrations at the onset of LRR as
pharmacodynamic endpoint (rather than the more tradi-
tional approach of measuring the concentration at offset in
a sleeping time experiment) is that the concentrations are
obtained under disequilibrium conditions. This enables
identification of the compartment which is indistinguish-
able from the site of action, which is the compartment
where the free drug concentration at onset of LRR is
independent of the rate of infusion (Fig. 1a). These studies
showed that only in cerebrospinal fluid (CSF), but not in
plasma or brain tissue, the phenobarbital concentration at
onset of LRR is independent of the infusion rate. Thus, in
this manner the CSF was identified as a compartment that,
unlike blood plasma or whole brain tissue, is pharma-
cokinetically indistinguishable from the site of action
(Fig. 1b) [5]. A further advantage of the use of CSF con-
centrations is that, due to the absence of significant protein
concentrations, they reflect free drug concentrations in the
brain which presumably are pharmacologically more rele-
vant compared to total brain concentrations. In subsequent
investigations from Levy’s laboratory and others these
investigations were extended to different drugs and dif-
ferent pharmacodynamic endpoints (Table 1). For example
studies on the sedative effects were extended to other
barbiturates with different physicochemical properties(e.g.
heptabarbital) and drugs with different molecular targets
such as, ethanol [10] benzodiazepines (e.g. diazepam,
oxazepam [11, 12]), zoxazolamine (and its metabolite
chlorzoxazone, [13]), and salicylamide [14]. Next the
studies were extended to other pharmacodynamic end-
points (e.g. convulsant effects of pentylenetetrazole, PTZ)
[15, 16]. These studies showed that for most of the drugs
studied, the CSF concentrations are uniquely representative
for the target site concentrations, while for other drugs
(salicylamide and PTZ) there is rapid equilibrium between
the concentrations in plasma, brain tissue, and CSF making
them equally useful for use in pharmacodynamic investi-
gations (Table 1). The principles of identifying a com-
partment in which drug concentrations are in direct
equilibrium with effect site concentrations, and the use of
CSF in pharmacodynamic studies on CNS active drugs
were adopted by other research groups [17–21]. This
Fig. 1 a Schematic representation of drug concentration versus time
profiles at three different infusion rates in the plasma (continuous
lines) and at the site of action (dashed lines). The time of onset of a
pharmacologic effect is indicated by arrows. The representation is a
simulation of a two-compartment system with a drug clearance of
0.029 l/h, a terminal drug half-life of 24 h and infusion rates of 0.42,
2.5 and 4.2 mg/min. It should be noted that the drug concentration in
plasma at onset of effect decreases with decreasing infusion rate.
b Effect of infusion rate on the concentration of phenobarbital in
serum (total and unbound drug, respectively), brain and CSF of
female rats at the onset of loss of righting reflex. Results are the mean
of five to nine animals per group, with the vertical line indicating 1
SD. Infusion rate had a significant effect (p\ 0.001 by one-way
analysis of variance) on drug concentrations in serum and brain but
not on concentrations in CSF. The symbols above the vertical bars
indicate significant differences from the results produced by the
lowest infusion rate (*p\ 0.002; p\ 0.01; ?p\ 0.05; Newman-
Keuls test). Reproduced from Danhof and Levy 1984 [5]
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generated an interest in the use of CSF drug concentrations
in investigations on the pharmacodynamics of CNS active
drugs (for review see: [22]).
Enantiomers
As indicated above, another potentially confounding factor
is enantio-selectivity, in particular if these drugs are
administered as their racemic mixtures. In this respect it was
appreciated that racemic mixtures are in principle mixtures
of two drugs which differ in pharmacokinetics and phar-
macodynamics (both qualitatively and quantitatively).
Consequently the effect of a racemic drug depends on the
interactions between the two enantiomers. To study such
interactions properly, enantio-selective assays are needed,
which allow measurement of the concentrations of each of
the enantiomers separately [23]. This also applies when the
effect of a single enantiomer is studied, as interconversion
cannot a priori be excluded. To avoid complexities caused by
enantio-selective disposition Levy and his associates were
careful in the selection of the model drugs for their investi-
gations. For example in the studies on the anesthetic effects,
phenobarbital and heptabarbital were chosen as model drugs
rather than the widely used thiopental [24].
(Inter)active metabolites
There are numerous examples where active metabolites
contribute to or are even entirely responsible for the effect
following drug administration. With regard to the contri-
bution of drug metabolites to the pharmacological effect, it
was emphasized that metabolites can not only contribute to
the effect through their intrinsic pharmacological activity,
but that metabolites can also be inter-active (e.g. can
compete with the parent drug for binding to target site
while having no intrinsic activity). For this reason it is
important that, when the pure metabolite is available, its
effects are studied in combination with the parent drug at a
relevant concentration range [11].
In the first paper we applied this concept to the possible
interaction of the metabolite p-hydroxy-phenobarbital to
the sedative effects of the parent drug phenobarbital [5]. In
healthy animals no measurable concentrations of p-hy-
droxy-phenobarbital above the limit of quantification were
observed at onset of LRR during a zero-order infusion of
phenobarbital, nor at the offset of LRR following admin-
istration of an intravenous bolus dose of 140 mg/kg phe-
nobarbital. Furthermore, upon direct administration of p-
hydroxy-phenobarbital (0.0824 mg/min) in combination
with its parent drug (0.824 mg/min), measurable concen-
trations in blood and CSF were detected, but there was no
effect on the concentration of phenobarbital at onset of
LRR. These results showed that there was no interaction
between phenobarbital and its major metabolites [5]. Using
a similar approach as for phenobarbital, Klockowski and
Levy found that for diazepam the concentrations in CSF
reflect the concentrations in the biophase [11]. The CSF
concentrations could therefore be used to estimate the
Table 1 Studies on the identification of a site where drug concentrations were in direct equilibrium with the target site
Studies in which CSF concentrations were
identified as the compartment ‘pharmacokinetically
indistinguishable from the site of action’
Studies in which concentrations in serum, brain
and CSF at onset of a defined pharmacologic
effect were independent of infusion rate
CNS depressants
Pharmacodynamic endpoints
Onset of loss of righting reflex
Offset of loss of righting reflex
Effect of infusion rate on phenobarbital
concentrations in serum, brain and cerebrospinal
fluid of normal rats at onset of loss of righting
reflex [5]
Pharmacodynamics of diazepam and its active
metabolites in rats [11]
Effect of repeated blood sampling on the
pharmacodynamics of phenobarbital in rats [91]
Pharmacodynamics of the hypnotic effect of
salicylamide in rats [14]a
CNS stimulants
Pharmacodynamic endpoints
Onset of seizures (first myoclonic
jerk, twitch)
Onset of maximal seizures (tonic
flexion of the forelimbs and (usually)
tonic extension of the hindlimbs)
Pharmacodynamics of theophylline-induced
seizures in rats [15]
Chronic theophylline administration has no
apparent effect on theophylline concentrations
required to produce seizures in rats [92]a
Effect of infusion rate on pentylenetetrazol
concentrations in serum, brain and
cerebrospinal fluid of rats at onset of
convulsions [34]
Most titles in this table are shortened titles. Full titles of the published papers include Kinetics of Drug Action in Disease States, followed by a
number (I-XLV), and the short title represented in this table
a Titles are the full title of the published paper
450 J Pharmacokinet Pharmacodyn (2015) 42:447–462
123
relative potency of the benzodiazepines and their respec-
tive metabolites, which was about 2:3:1:1 for diazepam and
its metabolites desmethyldiazepam, temazepam and oxa-
zepam. In addition, it was found that upon the adminis-
tration of diazepam, the metabolite desmethyldiazepam
contributes substantially to the hypnotic activity of the
parent drug, despite its relatively minute concentration in
serum [11].
A potential problem in studying the role of (inter)active
metabolites is the fact the full metabolite profile of a given
drug is rarely known. In this respect it is important that the
possible role of (unknown) active metabolites may be
explored indirectly by varying the rate and route of
administration as has been elegantly demonstrated for
heptabarbital [25]. Here oral administration is particularly
informative in cases where there is a significant first-pass
effect as this typically leads to large differences in the
exposure to metabolites relative to the concentrations of the
parent drug. Classical examples in which a difference in
concentration–effect curves was observed after different
routes of administration are quinidine [26], and verapamil
[27, 28]. Meanwhile, changing the rate and route of
administration and characterizing the pharmacodynamics
upon the administration of different doses has become an
accepted approach in the validation of PK–PD models as is
illustrated for midazolam [29], alfentanil [30], and N6
cyclopentyl-adenosine [31].
Acute tolerance as a potential complicating factor
Acute tolerance to drugs can develop very rapidly. Since it
cannot be ruled out that the rate and/or extent of acute
functional tolerance is not affected by disease conditions, it
is necessary to minimize or avoid acute tolerance in the
experimental setting [11, 32]. Here an important factor is
that the drug effect rather than the drug concentrations may
be the driver of pharmacodynamic tolerance development.
For example, for barbiturates it was observed that the
magnitude of acute tolerance was related to the maximum
drug concentration at the site of action or the maximum
intensity of the pharmacological effect, rather than the
duration of exposure [33]. Therefore in Levy’s investiga-
tions, focus was placed on the drug concentration at the
onset of effect rather than the offset, as in that situation the
duration of the effect is equal to zero (see for example: [5,
11, 34]). In the first paper the development of acute tol-
erance development to phenobarbital under healthy con-
ditions was studied by comparison of the concentrations at
onset of LRR during a zero-order infusion relative to the
concentrations at offset of LRR following administration of
a bolus dose. These concentrations were equal, confirming
that tolerance development had not occurred within the
timeframe of the studies [5].
In summary, in the series of publications ‘‘Kinetics of
Drug Action in Disease States’’ Levy and his associates
have developed several concepts and approaches to sepa-
rate pharmacokinetic from pharmacodynamic variability,
which continue to be of value in developing pharmacoki-
netic-pharmacodynamic models.
Exploring variability in pharmacodynamics
The concepts discussed above were applied to explore
inter-individual variation in pharmacodynamics. The
results of these studies are summarized in the Tables 2, 3,
and 4. Levy started at a very early stage with exploring the
effects of physiological variables on the pharmacodynam-
ics. A summary of the various physiological factors and
their effects on the pharmacodynamics of CNS active drugs
that have been studied is presented in Table 2. The studies
on the effects of disease on the pharmacodynamics focused
on renal failure, liver failure, diabetes, hypertension
(Table 3). As a rule, in these investigations the changes in
pharmacodynamics were studied in two different models of
a given disease, to exclude a possible artifact caused by the
methods that had been used to introduce the disease, rather
than the disease per se. Furthermore, extensive serum
biochemistry was obtained to confirm the presence and the
severity of the disease and to exclude to the best of our
ability, co-morbidity. In these investigations, the most
profound changes in brain sensitivity were observed in
experimental renal failure [13, 16, 35–37].
The effect of renal dysfunction was studied by using two
distinctly different animal models of renal failure; uranyl
nitrate was used to chemically induce renal dysfunction
and bilateral ureteral ligation was used to mechanically
induce renal dysfunction [13, 16, 35–37]. In rats with
experimental renal failure, significantly increased brain
sensitivity for the sedative effect of phenobarbital was
found, as reflected by a lower threshold dose for induction
of LRR and lower phenobarbital concentrations in plasma,
brain tissue and CSF at onset of LRR [35].
Given the importance of this observation, the mecha-
nism(s) of this change were explored in a number of sub-
sequent studies (Table 4). Since it could not be excluded a
priori that (severe) renal failure is associated with a change
in target site distribution, resulting from changes in the
permeability of the blood–brain barrier, and/or the
expression and function of transporters at the blood–brain
barrier, the target site distribution kinetics were revisited.
To this end the influence of the infusion rate on the phe-
nobarbital plasma, tissue and CSF concentrations at onset
of LRR was determined in rats with experimental renal
failure. These studies showed that the kinetics of biophase
equilibration was indeed altered in renal failure, since,
J Pharmacokinet Pharmacodyn (2015) 42:447–462 451
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unlike the situation in normal rats, the CSF concentration at
onset of LRR changes with the infusion rate [35]. How-
ever, at each infusion rate the concentration at LRR was
lower in renal failure rats, compared to their healthy con-
trols. On the basis of extrapolation to a hypothetical infu-
sion rate of zero, the change in brain sensitivity was
confirmed and the true magnitude of this change could be
quantified [35].
Following a ‘‘systems approach’’ the next step was to
determine whether changes in brain sensitivity in experi-
mental renal failure are also observed for drugs with a
similar, a related or a different mechanism of action. For
example, it is well established that the actions of barbitu-
rates originate at least in part from an interaction with
GABA receptor complex [38, 39]. For ethanol on the other
hand, the sedative effect is at best only in part related to the
GABA receptor [36, 40]. Interestingly, for the barbiturate
heptabarbital a similar change in brain sensitivity was
observed compared to phenobarbital [41]. For ethanol also
increased brain sensitivity was observed, albeit that the
magnitude of this change was smaller than for barbiturates
[36]. For the muscle relaxant zoxazolamine, with a dis-
tinctly different mechanism of action, an increased brain
sensitivity was also found in rats with renal failure [13].
These findings indicate that in general renal failure is
associated with an increased sensitivity to the actions of
sedative and anesthetic drugs, which is not related to a
specific mechanism of action.
Table 2 Influence of abnormal physiological conditions on the pharmacodynamics of CNS depressants and CNS stimulants
CNS depressant drugs CNS stimulating drugs
Pregnancy Effect of pregnancy on phenobarbital concentrations at onset of
loss of righting reflex in rats [93]
Effect of pregnancy on ethanol concentrations at onset of loss of
righting reflex in rats [10]a
Effect of pregnancy on the relationship between




Effect of experimental fever on phenobarbital concentrations at
onset of loss of righting reflex in rats [95]
Effect of fever on the pharmacodynamics of
theophylline-induced seizures in rats [96]
Effect of body temperature on the convulsant
activity of pentylenetetrazol in rats [97]
Acute
hypovolemia
Effect of acute hypovolemia on the pharmacodynamics of
phenobarbital in rats [98]
Effect of experimental hypovolemia on the pharmacodynamics and
pharmacokinetics of desmethyldiazepam [99]
Effect of hypovolemia on the pharmacodynamics of zoxazolamine
in rats [100]
Effect of acute hypovolemia on theophylline-induced
neurotoxicity in rats [101]
Food or fluid
imbalances
Effects of acute starvation on the pharmacodynamics of
phenobarbital, ethanol and pentylenetetrazol in rats and effects of
refeeding and diet composition [102]b
Effects of acute fluid overload and water deprivation on the
hypnotic activity of phenobarbital and the neurotoxicity of
theophylline in rats [103]b
Effects of acute starvation on the pharmacodynamics
of phenobarbital, ethanol and pentylenetetrazol in
rats and effects of refeeding and diet composition
[102]b
Effects of acute fluid overload and water deprivation
on the hypnotic activity of phenobarbital and the




Effect of adrenalectomy on the hypnotic activity of phenobarbital,
the neurotoxicity of theophylline and pain sensitivity in rats
[104]b
Effect of adrenalectomy on the hypnotic activity of
phenobarbital, the neurotoxicity of theophylline
and pain sensitivity in rats [104]b
Nicotine Effect of nicotine on the pharmacodynamics and pharmacokinetics
of phenobarbital and ethanol in rats [105]
Drug-drug
interactions
Effect of cyclosporine on the pharmacodynamics and
pharmacokinetics of a barbiturate (heptabarbital) in rats [106]
Potentiating effect of L-tryptophan on the hypnotic action of
phenobarbital and ethanol in rats [107]
Effects of contraceptive steroids on the pharmacodynamics of
ethanol in rats [108]
Most titles in this table are shortened titles. Full titles of the published papers include Kinetics of Drug Action in Disease States, followed by a
number (I-XLV), and the short title represented in this table
a Titles are the full title of the published paper
b If both CNS depressants and CNS stimulants are reported in one published paper, the paper is mentioned twice in the table
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To mechanistically understand the observed changes in
pharmacodynamics, Levy was particularly keen on studying
the effects of endogenous compounds which accumulate in
the body in renal failure and which alter the pharmacody-
namics causing the increased brain sensitivity (Table 4). In
the search for the identification of such mediators, endoge-
nous components from uremic plasma were isolated by
dialysis. Next the effect of dialyzable components from the
blood of uremic rats was studied by administering the dia-
lysate to normal rats and then to study the pharmacody-
namics of phenobarbital by determining the CSF
concentration at onset of LRR [42]. This study showed a
change in brain sensitivity very similar to the change
observed in rats with experimental renal failure [42]. Next, a
single component from the dialysate on the pharmacody-
namics of barbiturates was studied, i.e. urea. Urea infusion
Table 3 Influence of disease conditions on the pharmacodynamics of CNS depressants and CNS stimulants
CNS depressants CNS stimulants
Renal
dysfunction
Effect of experimental renal dysfunction on phenobarbital
concentrations in rats at onset of loss of righting reflex [35]
Effect of experimental renal dysfunction on the
pharmacodynamics of ethanol in rats [36]
Effect of experimental renal failure on the
pharmacodynamics of zoxazolamine and chlorzoxazone
[13]
Effect of orally administered activated charcoal on the
hypnotic activity of phenobarbital and the neurotoxicity of
theophylline administered intravenously to rats with renal
failure [109]b
Effect of experimental renal failure on the
pharmacodynamics of theophylline-induced seizures in rats
[37]
Disparate effects of pentylenetetrazol in rats as a function of
renal disease model and pharmacologic endpoint [16]
Effect of orally administered activated charcoal on the
hypnotic activity of phenobarbital and the neurotoxicity of
theophylline administered intravenously to rats with renal
failure [109]b
Liver disease Effect of experimental liver diseases on the
pharmacodynamics of phenobarbital and ethanol in rats
[110]
Effect of hepatic cirrhosis on the pharmacodynamics and
pharmacokinetics of mivacurium in humans [111]a
Effect of experimental liver disease on the neurotoxicity of
theophylline in rats [112]
Diabetes Effect of experimental diabetes on phenobarbital
concentrations in rats at onset of loss of righting reflex
[113]
Hypertension Effect of experimental hypertension on the
pharmacodynamics of phenobarbital in rats [114]
Hyperthyroidism Effect of experimental hyperthyroidism on the hypnotic
activity of a benzodiazepine (oxazepam) in rats [12]
Effect of experimental thyroid disorders on the
pharmacodynamics of phenobarbital, ethanol and
pentylenetetrazol [115]b
Effect of experimental thyroid disorders on the
pharmacodynamics of phenobarbital, ethanol and
pentylenetetrazol [115]b
Most titles in this table are shortened titles. Full titles of the published papers include Kinetics of Drug Action in Disease States, followed by a
number (I-XLV), and the short title represented in this table
a Titles are the full title of the published paper
b If both CNS depressants and CNS stimulants are reported in one published paper, the paper is mentioned twice in the table
Table 4 Influence of systemic components of renal dysfunction on the pharmacodynamics of CNS depressants and CNS stimulants
CNS
depressants
Effect of dialyzable component(s) of uremic blood on phenobarbital concentrations in rat at onset of loss of righting reflex [42]
Acute effect of urea infusion on phenobarbital concentrations in rats at onset of loss of righting reflex [24]
Effect of elevated plasma creatinine concentrations on the hypnotic action of phenobarbital in normal rats [116]
Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: Implications of severe
hypoalbuminemia [43]
CNS stimulants Effect of the dialyzable component(s) of uremic blood on theophylline neurotoxicity in rats [117]
Titles in this table are shortened titles. Full titles of the published papers include Kinetics of Drug Action in Disease States, followed by a number
(I-XLV), and the short title represented in this table
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resulted in experimental azotemia (i.e. blood urea nitrogen
concentrations in the same range as in rats with experimental
renal failure), and was found to affect the distribution
kinetics of phenobarbital. However, the brain sensitivity was
not changed as the CSF concentrations of phenobarbital at
LRR were unaffected [24]. Finally it was demonstrated that
nephrotic syndrome caused hypo-proteinemia and an asso-
ciated decrease in plasma protein binding of heptabarbital
(i.e. a change in pharmacokinetics) [43]. But again the drug
concentration in CSF at the pharmacological endpoint was
not changed, indicating that nephrotic syndrome has no
effect on the pharmacodynamics.
The influence of renal failure was also studied for
another pharmacodynamic endpoint: seizure activity as a
measure of neurotoxicity. For the convulsant effect of PTZ,
disparate effects of renal failure were observed, both with
respect to the pharmacodynamic endpoint and the method
that was used for induction of renal failure [34]. No dif-
ference in the concentration of PTZ required for induction
of minimal seizures was observed between normal rats and
rats with chemically or surgically induced renal failure. In
contrast, rats with chemically induced renal dysfunction,
required higher PTZ concentrations for the induction of
maximum seizures, whereas the ureter-ligated rats con-
vulsed at lower concentrations of PTZ than did the corre-
sponding control animals [16]. It was suggested that renal
failure may have differential effects on the threshold for
induction of seizures and the spreading of the seizure
activity.
The studies on the convulsant effects were extended to
the (at that time) still widely used brochodilator theo-
phylline. This drug can cause serious side effects, including
life-threatening generalized seizures [44, 45]. Levy and his
associates investigated the wide variability in theophylline
plasma concentrations associated with seizures. To this end
the theophylline concentration in the CSF at the onset of
seizures, which was found to be independent of the rate of
infusion, was used as pharmacodynamic endpoint [15].
Using different models to induce renal dysfunction, it was
found that the neurotoxicity of theophylline was not
changed after chemical induction of renal failure (uranyl
nitrate), while a higher incidence of neurotoxicity was
found after mechanical induction (ureter ligation) of renal
dysfunction [37].
The impact on pharmacodynamics research:
towards physiology based pharmacodynamic
models
In the previous paragraphs an account is presented of
Levy’s research on variation in pharmacodynamics as
described in the publications in the series ‘‘Kinetics of
Drug Action in Disease States’’. By applying experimental
approaches that enable a strict separation between phar-
macokinetics and pharmacodynamics it was shown
unequivocally that besides variation in pharmacokinetics,
variation in pharmacodynamics is a significant determinant
of variation in drug response. Moreover, evidence of a
wide disparity in the effects of disease on the pharmaco-
dynamics of CNS active drugs was observed. However, the
evidence that had been generated was still largely obser-
vational. Little was known on the underlying mechanisms
of the observed changes. Moreover, it was still largely
unknown how the observed variation in experimental
models of disease, would translate into inter-individual
variation in humans. The next challenge was therefore to
develop the mechanism-based understanding of this vari-
ation in pharmacodynamics. Analogous to the development
of the theory and application of ‘‘physiology-based phar-
macokinetics’’ (PBPK) to explain and predict variation in
drug concentrations [46, 47], it was deemed necessary to
develop ‘‘physiology-based pharmacodynamics’’(PBPD) as
a novel scientific basis for the understanding and prediction
of variation in drug effects.
PBPD models contain specific expressions to characterize
in a strictly quantitative manner processes on the causal path
between exposure (in terms of concentration at the target
site) and the drug effect (in terms of the change in biological
function). Pertinent processes on the causal path are: (1)
target site distribution, (2) target binding and activation and
(3) transduction and homeostatic feedback. PBPD models
connect pharmacokinetics to ultimately the drug effects on
disease progression (Fig. 2). As is the case for PBPK models,
an important feature of PBPD models is the strict separation
between drug specific properties (in terms of the binding and
activation of the target) and system-specific properties (in
terms of transduction processes).
To develop meaningful PBPD models it was necessary
to overcome a number of technical challenges. Levy’s
research was based on a single observation of the drug
concentration and the effect intensity. However PBPK and
PBPD focus on the modeling of the time course of drug
concentrations and effect, respectively. Hence experimen-
tal methods needed to be developed that enabled multiple
observations per individual subject. Second, continuous
and meaningful measures of the pharmacological effect are
needed to explore the full relation between drug concen-
tration and effect intensity. Finally, computational tech-
niques needed to be developed to identify complex, often
non-linear, PBPD models.
Target site distribution
In the original studies CSF samples were collected by
puncture of the cisterna magna, limiting the number of
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samples per individual animal to one. To enable time
course studies, the experimental technique of implantation
of a permanent cannula in the cisterna magna was devel-
oped. The first study showing the feasibility of time course
studies in CSF focused on heptabarbital [48]. Next the
technique was applied to study the CNS distribution of
desglycinamide-arginine vaspressin (DGAVP) as prototype
peptide [49]. By applying the ‘‘unit impulse response’’
technology, analyzing the concentration profiles following
intravenous and intracerebral administration, the input
profile in the CNS could be determined [50]. Using this
technology, the brain distribution kinetics of the enan-
tiomers of baclofen was determined, showing remarkable
differences in the brain distribution kinetics between the
enantiomers [51]. Comparison of the input profile obtained
on the basis of CSF concentrations with the ones obtained
on the basis of EEG effect parameters as a pharmacody-
namic endpoint showed markedly different input profiles
indicating that CSF concentrations of baclofen are not
pharmacokinetically identical to the target site concentra-
tions [52]. A systematic review of this topic indeed showed
that the use of CSF concentrations is limited in predicting
the effect of a centrally acting drug, presumably as a result
of compartmentalization within the brain [53]. Recent
studies, using microdialysis to determine drug concentra-
tion profiles, have shown that brain distribution kinetics are
complex and often non-linear due to regional differences
blood–brain barrier permeability as well as regional
differences in the expression and function of transporters at
the blood–brain barrier [54–56]. Meanwhile, the first PBPK
models for characterization drug distribution in the central
nervous systems have been proposed, for model drugs
paracetamol, quinidine, and methotrexate [55, 57, 58]. It is
anticipated that PBPK concepts will increasingly be
applied to characterize target distribution kinetics [57].
Target binding and activation
Fundamental research on the mechanisms of variation in
pharmacodynamics is based on the analysis of full in vivo
concentration–effect relationships. This requires the avail-
ability of continuous measures of the pharmacological
effect, which can be obtained continuously/repeatedly
within individual subjects and which are meaningful with
regard to the therapeutic effects and/or the safety of the
drug under investigation [59]. A major development in the
research on pharmacodynamics was the creation of
chronically instrumented animal models in which, for a
variety of endpoints, the time course of the drug effect
could be determined in conjunction with the time course of
the drug concentration in blood plasma. This enabled the
derivation of concentration–effect relations in individual
animals for a variety of drugs (Table 5). Following Levy’s
approach, for prototype compounds from each of these
classes (i.e. midazolam, alphaxalone, N6-cyclopentyl ade-
nosine, alfentanil, remoxipride) it was demonstrated that
Fig. 2 Schematic representation of physiology-based pharmacody-
namic (PBPD) modeling. PBPD models connect pharmacokinetics to
the drug effects on disease progression, and contain expressions to
describe the processes on the causal path between drug administration
and effect (target site distribution, target binding and activation, and
transduction and homeostatic feedback)
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unique concentration–effect relations had been obtained
that were independent of the rate and route of administra-
tions [60] [29–31] [61]. In contrast for the 5-HT1A receptor
agonists buspirone, it was demonstrated that the active
metabolite 1-(2-pyrimidinyl)-piperazine contributes sig-
nificantly to the effect following administration of the
parent drug [62]. Furthermore, for benzodiazepines and 5
HT1A receptor agonists the role of interactive metabolites
was studied by direct administration [63] [64], while for
synthetic opioids and dopamine D2 receptor antagonists,
the analysis of the effect upon repeated administration
enabled the characterization of acute functional tolerance
development [30, 61].
A milestone in the research on pharmacodynamics was
the incorporation of concepts from receptor theory for the
prediction of variation in concentration–effect relations
[65]. In theory, the relationship between the drug concen-
tration and the intensity of the biological response depends
on drug- and biological system specific factors (Fig. 3).
This explains why for a given drug, the concentration–
effect relationship can differ between tissues, between
species and, within a single species, also between indi-
viduals. Classical receptor theory combines two indepen-
dent parts to describe drug action: an agonist-dependent
part and a system dependent part and therefore constitute a
unique scientific basis for the prediction of variation in
in vivo concentration–effect relationships Briefly, the
agonist dependent part describes the target activation,
usually on the basis of a hyperbolic function. The target
activation depends on the intrinsic efficacy of the drug
under investigation and the receptor density. Next the
system dependent part describes the translation of the tar-
get activation into the response on the basis of a system-
specific transducer function. This transducer function can
take any shape (i.e. linear, hyperbolic) [65]. In a number of
investigations it was shown that for a given target, receptor
models can be identified by simultaneously analyzing
concentration–effect relations of a training set of ligands
with different binding affinity and intrinsic efficacy,
yielding estimates of the in vivo binding affinity and
intrinsic efficacy of each of the drugs in the training set, as
well as the shape and location of the system specific non-
linear transducer function. For GABAA-receptor agonists,
adenosine A1 receptor agonists, (semi-) synthetic opioids
and 5-HT1A receptor agonists highly significant correla-
tions were observed between the affinity and intrinsic
efficacy estimates in vivo and corresponding estimates in
in vitro bioassays confirming the validity of the approach
[64, 66–68]. Thereby it was demonstrated that for indi-
vidual compounds, in vivo drug concentration–effect
relationships can be predicted on the basis of information
from these in vitro assays, provided that the effects of
potentially confounding pharmacokinetic factors are either
excluded or accounted for, as was demonstrated for the
5-HT1A receptor agonist flesinoxan, which has a much
lower in vivo potency than expected on the basis of its
receptor affinity, due to active efflux mechanisms at the
blood–brain barrier [69]. Successful applications of
receptor theory include prediction of the selectivity of
Table 5 Overview of studies in which a continuous measurement of the pharmacological effect was used together repeated measurement of
pharmacokinetics
Drug Endpoint
Benzodiazepines ? related GABA receptor agonists EEG parameters [29, 60, 66]
Cyclopentyl-adenosine A1 receptor agonists Hemodynamic parameters [31]
Biochemical parameters: lipolysis [118]
Opioids EEG effect parameters [119, 120]
Anti-nociceptive effect; Respiratory depression [71, 121]
5-HT1A receptor agonists Body temperature [64, 83]
Dopamine D2 receptor agonists Receptor occupancy [122, 123]
Prolactin responses [61]
Fig. 3 The relationship between drug concentration and the intensity
of the biological response depends on drug- and biological system
specific factors. Drug specific properties are the target binding affinity
and the intrinsic efficacy, which govern the target activation. A
biological system-specific transducer function describes the relation
between the target activation and the effect. Reproduced from: van
der Graaf and Danhof [67]
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action of N6 cyclopentyladenosine analogues (inhibition of
lipolysis versus bradycardia [70]; Fig. 4), prediction of the
selectivity of action of semi-synthetic opioids (anti-noci-
ception versus respiratory depression [71]), prediction of
concentration–effect relations of (semi-) synthetic opioids
in man [72, 73], and the prediction of variation in con-
centration–effect relations of alfentanil (Fig. 5) [74].
Transduction and homeostatic feedback
In PK-PD modeling the concept of ‘transduction’ refers to
the processes that govern the transduction of target acti-
vation into the response in vivo. Modeling of transduction
can be complex because it is typically highly non-linear.
Also, complex homeostatic feedback mechanisms and/or
compensatory pathways might attenuate or alter the
response of the in vivo concentration–effect relationship
[75–77]. When transduction in vivo is slow (i.e. operating
at rate constants in the order of minutes to hours, or even
days) transduction will also determine the time course of
drug effect. Moreover, in this situation homeostatic feed-
back mechanisms might cause complex patterns of the
pharmacodynamics, such as fluctuating (oscillating) phar-
macological effect versus time profiles, dependency of
drug effects on the rate of administration, tolerance
development upon chronic treatment and/or rebound
effects upon cessation of chronic treatment. This under-
scores the importance of the modeling of time-dependent
transduction mechanisms. To account for time-dependent
transduction in PK-PD modeling, a variety of models have
been proposed that are all based on concept of the indirect
pharmacological response model that was proposed by
Levy in 1969 to account for the observed delay in the
anticoagulant response of warfarin [7]. This concept has
been formalized in a large series of publications by Jusko
et al. [78–81]. Turnover models can also be linked in the
Fig. 4 PK–PD modeling of anti-lipolytic effects of Adenosine A1
receptor agonists in rats: prediction of tissue-dependent efficacy
in vivo. a Relationship between intrinsic efficacy in an in vitro (GTP-
shift) and in vivo (log s) bioassay for the effect of a series of A1
receptor agonists on heart rate and lipolysis (as measured by
nonesterified fatty acids, NEFAs), respectively. The difference in
the intercept for the two effects is explained by the difference in
receptor density between adipose tissue and cardiac tissue. b Rela-
tionship between intrinsic efficacy in an in vitro bioassay (GTP shift)
and in vivo intrinsic activity (a) for the effects on heart rate and
lipolysis, respectively. The graphs show that partial agonists with
GTP shift values between 1 and 5 display the highest selectivity of
action for the effect lipolysis versus heart rate. Reproduced from van
der Graaf et al. [70]
Fig. 5 PK–PD analysis of the EEG effect of alfentanil in rats
following in vivo l-opioid receptor (MOP) knockdown with b-
flunaltrexamine. Pretreatment with b-flunaltrexamine resulted in an
approximately 60 % reduction of functional MOP receptors at 35 min
and at 24 h post administration. A parallel shift in the concentration–
effect relationship without a major change in maximum effect was
observed. This reduction in functional receptors is consistent with the
observation that the MOP receptor functions with a high receptor
reserve. Reproduced from Garrido et al. [74]
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sense that the output of one model serves as input for
another. Using these cascading turnover models, interme-
diary processes between the drug–target interaction and the
ultimate biological response can be described; this
approach has been applied to modeling the effects of cor-
ticosteroids on the activity of the enzyme tyrosine amino
transferase (TAT) [82]. In addition, the effect versus time
profiles of the hypothermic response can also be described
with a complex turnover model [64]. Together with allo-
metric scaling the hypothermic response of two selective
5-HT1A receptor agonists, buspiron and ipsapirone, could
be predicted in humans [83]. This study showed that the
importance of scaling factors in the interspecies extrapo-
lation of drug effects [84].
Disease systems analysis
Levy’s research focused on the effects of disease on drug
action (i.e. on disease as a factor causing inter-individual
variation in drug response). However, drug treatment may
also have an effect on the disease. In many instances drug
effects are symptomatic, but drugs may also modify disease
process and thereby modify disease progression. This is
particularly important for chronic progressive diseases.
Traditionally, descriptive models have been used to char-
acterize drug effects on disease progression [85, 86].
Recently the concept of disease systems analysis has been
introduced, which aims to describe disease progression in a
more mechanistic manner. Disease systems analysis is based
on the ‘‘turnover model’’ concept to characterize variation in
the rate of disease progression. A pertinent feature of disease
systems models is the strict separation between drug effects
on the disease status (i.e. symptomatic effects) versus drug
effects on the disease process (disease modifying effects)
[84, 87]. In a series of simulations it has been demonstrated
that depending on the target and the mechanism of action,
these disease progression models have distinctly different
signature profiles, enabling the distinction between symp-
tomatic and disease modifying effects [88]. Meanwhile
cascading turnover models (i.e. models in which the output
from one turnover model serves as input for a second turn-
over model) have been proposed to cope with different time
scales in disease progression analysis [89]. This approach
has been successfully applied to the characterization of dis-
ease progression in type-2 diabetes mellitus and osteoporosis
[88, 90].
Conclusion
In this paper an overview has been given of Gerhard
Levy’s contributions to research on the interrelationships
between pharmacokinetics and pharmacodynamics in the
50 years following the publication of his seminal paper on
the kinetics of pharmacologic effects in 1966 [6]. It is
shown how the introduction of the theoretical concepts on
the ‘‘kinetics of pharmacological effects’’, the introduction
of the ‘‘turnover model’’, and ultimately the experimental
research on ‘‘the kinetics of drug action in disease’’, has
yielded the scientific basis for the development of ‘‘Phys-
iology-Based PharmacoDynamic’’ (PBPD) modelling as
novel scientific discipline, which in concert with ‘‘Physi-
ology-Based PharmacoKinetic’’ (PBPK) modelling con-
stitutes the theoretical basis for ‘‘Physiology-Based
Pharmacokinetic & Pharmacodynamic (PBPKPD) model-
ing a ‘‘systems approach’’ to the prediction of drug effects.
PBPKPD modelling connects observed drug concentrations
in plasma to the effects on disease progression. This will
enable the unravelling the complex interrelationships
between drug action and disease progression.
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Postscript MD was a postdoctoral fellow with Gerhard Levy (GL)
between October 1980 and September 1983, when GL started his
research on ‘‘Kinetics of Drug Action in Disease States’’. He was
involved in the research on identifying CSF as the compartment that
is pharmacokinetically indistinguishable from the site of action. MD
continued this work in collaboration with Dr. Donald R. Stanski at
Stanford University, developing experimental techniques for the
continuous monitoring of EEG effects in conscious rats and applying
non-linear mixed effects modeling concepts to the analysis of PKPD
models. The experiences in Buffalo and Stanford constituted the basis
for MD’s appointment to a faculty position at the newly established
Leiden Academic Centre for Drug Research (LACDR; Director of
Research: Dr. Douwe D. Breimer) at Leiden University in the
Netherlands in 1986. At LACDR he was given the task to establish an
independent research and education program in mechanism-based
PKPD modelling. Since 1986, 64 Ph.D. students, 20 postdoctoral
fellows and numerous MSc students have received their education
through this program. In these years MD continued communications
with GL, in particular also in the organization of the series of the
conferences on ‘‘Measurement and Kinetics of In Vivo Drug Effects’’,
which were held in Noordwijkerhout, every 4 years between 1990
and 2014 and in the annual course ‘‘Pharmacokinetic–Pharmacody-
namic Modelling—Concepts and applications’’, which originally was
offered both in Leiden and in Buffalo.
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